ResMed outlines FY 2027 $5.75B-$5.85B revenue outlook while targeting $1.85B+ shareholder returns (NYSE:RMD)
· seekingalpha.com
ResMed Q1 FY2027: revenue rose 7%, EPS jumped 14%, guidance held, and Astral sales ended.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...